Autres langues LAVA Therapeutics N.V.

Actions

LVTX

NL0015000AG6

Temps réel estimé Cboe BZX Autres places de cotation 21:05:19 16/05/2024			Varia. 5j.	Varia. 1 janv.
2,755 ^USD	-2,65 %		-11,90 %	+73,42 %

20/03	LAVA Therapeutics N.V. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
20/03	LAVA Therapeutics N.V. présente ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference	06/05
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference	06/05
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20/03
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20/03
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)	05/03
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	05/03
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	30/01
Sector Update: Health Care Stocks Softer Late Afternoon	25/01
Sector Update: Health Care Stocks Slipping Thursday Afternoon	25/01
Sector Update: Health Care	25/01
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	25/01
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	25/01
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	25/01
Top Premarket Gainers	25/01
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®	25/01
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	25/01
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	16/11
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues LAVA Therapeutics N.V.

Actions

LVTX

NL0015000AG6

Autres langues

Filtres